Foghorn Therapeutics Inc.
FHTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $22,602 | $34,155 | $19,228 | $1,319 |
| % Growth | -33.8% | 77.6% | 1,357.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $22,602 | $34,155 | $19,228 | $1,319 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $94,528 | $109,689 | $105,618 | $80,325 |
| G&A Expenses | $28,359 | $32,372 | $30,747 | $21,728 |
| SG&A Expenses | $28,359 | $32,372 | $30,747 | $21,728 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2,398 | $0 | $0 | $0 |
| Operating Expenses | $125,285 | $142,061 | $136,365 | $102,053 |
| Operating Income | -$102,683 | -$107,906 | -$117,137 | -$100,734 |
| % Margin | -454.3% | -315.9% | -609.2% | -7,637.1% |
| Other Income/Exp. Net | $16,063 | $13,706 | $8,255 | -$586 |
| Pre-Tax Income | -$86,620 | -$94,200 | -$108,882 | -$101,320 |
| Tax Expense | $0 | $4,226 | $0 | $0 |
| Net Income | -$86,620 | -$98,426 | -$108,882 | -$101,320 |
| % Margin | -383.2% | -288.2% | -566.3% | -7,681.6% |
| EPS | -1.58 | -2.34 | -2.62 | -2.78 |
| % Growth | 32.5% | 10.7% | 5.8% | – |
| EPS Diluted | -1.58 | -2.34 | -2.62 | -2.78 |
| Weighted Avg Shares Out | 54,899 | 41,974 | 41,591 | 37,171 |
| Weighted Avg Shares Out Dil | 54,899 | 41,974 | 41,591 | 37,171 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11,900 | $10,875 | $5,675 | $59 |
| Interest Expense | $0 | $0 | $0 | $1,906 |
| Depreciation & Amortization | $3,120 | $3,451 | $3,321 | $3,227 |
| EBITDA | -$97,165 | -$104,455 | -$113,816 | -$96,187 |
| % Margin | -429.9% | -305.8% | -591.9% | -7,292.4% |